Treatment of chronic hepatitis B in clinical practice with entecavir or tenofovir

Table 1 Baseline characteristics of patients included in entecavir studies[21]

Characteristic, n (%)1	ETV-022	ETV-027	Oriente	Virgil	King’s College Cohort	Italian cohort	Argentineancohort	Hong Kongcohort	Japan cohort	China cohort	China cohort 2	Taiwan cohort	Taiwan cohort 2	United States cohort	United States cohort 2	Australia
Ref.	[7]	[8]	[22]	[23]	[24]	[25[	[29]	[32]	[33]	[34]	[35]	[36]	[37]	[38]	[39]	[40]
n	354	325	190	243	154	418	169	222	474	230	1768	98	248	169	136	163
Age, yr (mean ± SD or range)	35 ± 132	44 ± 112	44 (35-54)3	43 ± 142	423	58 (18-82)4	51 ± 132	47 (21-77)4	47 (17-82)4	42 ± 122	36 (16-70)4	48 ± 132	39 (17-77)4	39 ± 122	39 ± 122	52 (24-86)4
Male	274 (77)	248 (76)	139 (73)	177 (73)	122 (79)	316 (76)	113 (77)	157 (71)	321 (67)	196 (85)	1414 (80)	67 (68)	172 (69)	100 (59)	83 (61)	113 (69)
Race					NR	NR		NR	NR	NR		NR				NR
White	140 (40)	193 (59)	60 (84)	114 (47)			143 (85)							7(4)	10 (7)
Asian	204 (58)	122 (38)	18 (9)	70 (29)			26 (15)				1768 (100)			162 (96)	126 (93)
Other	2 (< 1)	2 (< 1)	6 (3)	59 (24)
Region	Europe 24%, North America 13%, South America 14%, Australia and Asia 49%	Europe 48%, North America 9%, South America 11%, Australia and Asia 33%	Europe	Europe	Europe	Europe	South America	Asia	Asia	Asia	Asia	Asia		North America	North America	Oceania
Genotype			NR		NR		NR	NR		NR	NR	NR				NR
A	94 (27)	33 (10)		40 (22)					12 (3)					0
B	68 (19)	46 (14)		14 (8)					67 (16)					-61	-57
C	111 (31)	57 (18)		25 (14)					336 (81)					-39	-41
D	37 (10)	157 (48)		91 (50)		84 (90)			0 (0)					0
HBeAg negative	6 (3)	322 (99)	133 (70)	157 (65)	106 (69)	347 (83)	65 (39)	132 (59)	252 (53)	117 (51)	602 (34)	57 (58)	0 (0)	0 (0)	0 (0)	10 (6.1)
HBV DNA, log10 IU/mL1	9.62 (2.01)25	7.6 (1.8)25	5.94 (4.64-7.39)3	6.2 ± 1.73	4.6 (0.2)6	6.0 (1.5–9)4	6.88 (1.81)2	7.1 (4.0-> 8.8)4	6.7 (2.6-> 9.0)4	6.3 ± 1.43	6.74 (1.04-9.69)4	6.0 ± 1.53	7.6 (2.2-13.1)4	7.58 (3.77-9.70)4	7.48 (3.8-9.9)4	NR
ALT, IU/L1	140.5 (114.3)2	141 (114.7)2	71.5 (44-108)3	NR	NR	92 (11-2241)4	139 (231)2	92 (17-2168)4	70 (8-2121)4	68(3-2631)4	NR	138 (21-4190)4	201 (27-2415)4	62 (14-839)4	67 (14-1077)4	NR
Cirrhosis	26/329 (8)	15/303 (5)	07	57 (24)	52 (34)	202 (49)	38 (23)	0	102 (22)	74 (32)	NR	13 (14)	39 (16)	NR	NR	26(16)

¹Unless otherwise specified;

²Mean ± SD;

³Median (interquartile range);

⁴Median (range);

⁵log10 copies/mL;

⁶Mean ± SE;

⁷Advanced fibrosis in 34%. ALT: Alanine transaminase; NR: Not reported; NUC: Nucleos(t)ide analogue; VIRGIL: Vigilance against viral resistance; ETV: Entecavir.